Business Context and Reporting Period
Company: Lexaria Bioscience Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: July 23, 2019
Event: Entry into Material Definitive Agreements with Hill Street Beverage Company Inc. ("Hill Street").
Key Financial Metrics and Agreements
This filing details strategic partnerships rather than historical financial performance. Key financial terms include:
- CanPharm License Agreement (THC): Hill Street to pay up to US$1,800,000 in license fees, potentially settled via issuance of Hill Street voting common shares to Lexaria.
- CanPharm JV Agreement: Lexaria to pay a US$200,000 license fee to Hill Street for Health Canada license utilization, potentially settled via Lexaria restricted common shares.
- Hemp License Agreement (CBD): Non-exclusive license for CBD beverages subject to annual and usage fees (specific amounts not disclosed).
- Hemp JV Agreement: Lexaria to pay a US$50,000 license fee to Hill Street, potentially settled via Lexaria restricted common shares.
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a transactional report, not a financial statement.
Material Changes and Milestones
The agreements establish new revenue streams and strategic alliances effective July 23, 2019, with ten-year terms. Key milestones for the US$1,800,000 THC license fee include:
- Initial Payment: US$800,000 payable upon completion of Hill Street's acquisition of OneLeaf Cannabis Corp.
- Market Entry Payments: Up to US$500,000 in shares for each of the first two international markets entered.
- Share Issuance Constraints: Hill Street share issuance to Lexaria is capped at 9.99% of Hill Street's issued share capital.
- Escrow Conditions: The US$200,000 and US$50,000 fees payable by Lexaria to Hill Street are held in escrow until Hill Street evidences receipt of its Health Canada license.
Guidance, Risks, and Contingencies
Contingencies:
- Significant portions of the US$1,800,000 license fee are contingent on Hill Street's acquisition of OneLeaf Cannabis Corp. and successful entry into international markets.
- Lexaria's payments to Hill Street are contingent on Hill Street obtaining its Health Canada license.
- Valuation of share-settled fees depends on market prices (VWAP or closing prices) at specific future dates.
- Exclusion of Mexico from the geographic scope of the technology licenses.
Investor Verification Checklist
- Verify the status of Hill Street's acquisition of OneLeaf Cannabis Corp. to assess the likelihood of the initial US$800,000 payment.
- Confirm whether Hill Street has received its Health Canada license to determine if Lexaria's escrowed fees will be released.
- Monitor Hill Street's stock price to calculate the exact number of shares Lexaria may receive or issue under the variable pricing terms.
- Track Hill Street's entry into international markets to evaluate potential additional US$500,000 payments.
- Review the specific annual and usage fee structures for the CBD license, which were not detailed in this filing.